Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th ...

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...

(RTTNews) - Below are the earnings highlights for Alkermes plc (ALKS): Earnings: $36.83 million in Q1 vs. -$41.85 million in the same period last year. EPS: $0.21 in Q1 vs. -$0.25 in the same ...

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...

Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan has ...

Alkermes ALKS has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had ...

Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - - ...